Sensus Healthcare, Inc. (Sensus) is a US-based medical device company that provides non-invasive, cost-effective treatments for oncological and non-oncological skin conditions, with a primary focus on non-melanoma skin cancer and post-surgical keloid scar prevention.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Sensus conducts research and development (R&D) to advance its pipeline candidates for the treatment of non-melanoma skin cancer and other skin conditions, and to introduce new products and technologies. The company is continuing to drive its R&D to expand the indications into new areas of treatment, including psoriasis. In FY2025, the company incurred R&D expense of US$7.7 million, which as a percentage of revenue stood at 28% and grew 83% YoY. The R&D activities of the company contributed to its intellectual property portfolio. Sensus currently has a combination of patents, trade secrets, trademark law and non-disclosure agreements to establish and protect its proprietary rights in its products. The company holds patents for its products. Its patents span the technology in the field of superficial radiotherapy treatment.